Cerecor Inc (CERC)

NASDAQ
3.67
+0.15(+4.26%)
After Hours
3.52
-0.15(-4.09%)
- Real-time Data
  • Volume:
    1,366,552
  • Bid/Ask:
    3.52/3.63
  • Day's Range:
    3.43 - 3.70

CERC Overview

Prev. Close
3.52
Day's Range
3.43-3.7
Revenue
4.42M
Open
3.51
52 wk Range
1.98-4.5
EPS
-0.94
Volume
1,366,552
Market Cap
350.38M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,872,572
P/E Ratio
-
Beta
1.5
1-Year Change
42.25%
Shares Outstanding
95,471,843
Next Earnings Date
Aug 16, 2021
What is your sentiment on Cerecor Inc?
or
Market is currently closed. Voting is open during market hours.

Cerecor Inc News

Cerecor Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Cerecor Inc Company Profile

Cerecor Inc Company Profile

Employees
32

Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.

Read More
  • any opinion for CERC ? will go up to 5$ soon ?
    0
    • any precious idea what will happen with CERC please ?
      0
      • is it worths to entry right now ? what do you think folks ?
        0
        • $5 stock by November 15th, 2017
          0
          • Possibly more, if they announce good news in conjunction with the positive news they announced earlier this year with CERC-301. FDA already intends to fast track the approval for the MDD drug.
            0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.